ArticleOphthalmology science2026
Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We aimed to design, fabricate, and evaluate the pharmacokinetic properties of topotecan loaded with microneedle scleral patch (MSP) in rabbit eye. Methods: The MSP was fabricated using a 3-dimensional printed master mold. The second step involved making polydimethylsiloxane mold using a Sylgard 184 Silicone Elastomer Kit. The MSP was fabricated using a high-molecular-weight sodium hyaluronate biopolymer containing 90 conical microneedles (MNs) in a 15 × 6 array format. The MSP was loaded with 100 μg of topotecan to study its pharmacokinetics across choroid-retina complex. Results: The dimensions of MNs were uniform across the array measuring 548 ± 3.7 μm length, 336 ± 7.5 μm width, and 18 μm tip diameter. In the Conclusions: A single topotecan-loaded MSP (100 μg) achieved highly selective retinal tissue distribution, with a retinal-to-plasma ratio of 275-fold, which was 4.7-fold higher than intra-arterial chemotherapy (58.9) and 209-fold higher than intravenous chemotherapy (1.32), supporting its potential benefit for RB treatment. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.